Sionna Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	28.72	13.27	9.71	6.77
Research & Development	60.26	57.29	40.63	34.61
Total Operating Expenses	88.98	70.56	50.33	41.37
Operating Income	-88.98	-70.56	-50.33	-41.37
Interest Income	13.3	8.17	2.77	1.13
Other Non-Operating Income (Expense)	0.42	0.7	0.3	-
Total Non-Operating Income (Expense)	13.71	8.87	3.07	1.13
Pretax Income	-75.27	-61.69	-47.26	-40.24
Net Income	-75.27	-61.69	-47.26	-40.24
Net Income to Common	-75.27	-61.69	-47.26	-40.24
Shares Outstanding (Basic)	40	4	3	2,578
Shares Outstanding (Diluted)	40	4	3	2,578
Shares Change (YoY)	935.60%	31.56%	-99.89%	-
EPS (Basic)	-1.88	-15.99	-16.11	-15.61
EPS (Diluted)	-1.88	-15.99	-16.11	-15.61
Shares Outstanding	44.72	4.72	3.05	2.79
Free Cash Flow	-66.67	-52.81	-44.82	-37.94
Free Cash Flow Per Share	-1.67	-13.69	-15.28	-0.01
EBITDA	-88.34	-69.89	-49.75	-41.25
EBIT	-88.98	-70.56	-50.33	-41.37

Updated Mar 2, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q